Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06531629
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-07-27
Brief Title:
Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer Patients A Retrospective Cohort Study Based on Large-scale Population and Mendelian Randomization Analysis
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Second primary malignancy SPM significantly impacts the survival and prognosis of patients This study endeavors to identify risk and prognostic factors associated with SPM after first primary kidney cancer and construct predictive nomograms
Detailed Description:
In recent years with the advancement of cancer treatment techniques and the prolonged survival of patients the prevalence of Second primary malignancy SPM has been escalating emerging as a significant health issue among cancer survivors The goal of this study is to identify risk and prognostic factors associated with SPM after first primary kidney cancer and construct nomograms to provide clinical evidence The main questions this study aims to answer are 1 What are the risk factors associated with the prevalence of SPM after kidney cancer 2 What are the prognostic factors associated with the overall survival OS of kidney cancer patients with SPM 3 How to accurately predict the probability of developing SPM after kidney cancer and the OS of kidney cancer patients with SPM In this retrospective population-based cohort study Patients diagnosed with first primary kidney cancer between 2000 and 2020 were retrospectively enrolled from the Surveillance Epidemiology and End Results SEER database Researchers will concentrate on the risk and prognostic factors of SPM after kidney cancer and develop nomograms to forecast the development and overall survival OS of SPM after kidney cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None